ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,459.10
1.11%
US Tech 100
18,513.20
1.00%
Dow Jones
40,589.34
1.64%
Brent Oil
80.075
-1.79%
Bitcoin
67,909.56
3.22%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. LENZ Therapeutics Inc (LENZ) Quote

LENZ Therapeutics Inc

LENZ Therapeutics Inc (LENZ)

Sancus Lending Group Limited
23.86
-0.21
( -0.87% )
Updated: 15:46:00
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
23.86
Bid
23.85
Ask
24.02
Volume
43,861
23.61 Day's Range 24.84
14.42 52 Week Range 24.84
Market Cap
609.252M
Previous Close
24.07
Open
24.46
Last Trade
5
@
24.02
Last Trade Time
15:46:19
Financial Volume
$ 1,055,909
VWAP
24.074
Average Volume (3m)
199,791
Shares Outstanding
25,534,458
Dividend Yield
-
PE Ratio
-4.87
Earnings Per Share (EPS)
-4.88
Revenue
-
Net Profit
-124.65M

About LENZ Therapeutics Inc

Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert ... Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.lenz-tx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
LENZ Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker LENZ. The last closing price for LENZ Therapeutics was $24.07. Over the last year, LENZ Therapeutics shares have traded in a share price range of $ 14.42 to $ 24.84.

LENZ Therapeutics currently has 25,534,458 shares outstanding. The market capitalization of LENZ Therapeutics is $614.61 million. LENZ Therapeutics has a price to earnings ratio (PE ratio) of -4.87.

LENZ Latest News

More News

LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital

SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...

July 15 2024
GlobeNewswire Inc.

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024...

June 10 2024
GlobeNewswire Inc.

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...

May 30 2024
GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans

May 21 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

May 09 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 08 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 08 2024
Edgar (US Regulatory)

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 Capstone data from Phase 3...

May 08 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.069.449541284421.824.8420.997145822.92911229CS
45.932.8507795117.9624.8416.4918306519.06476693CS
127.1242.532855436116.7424.8414.4219979117.66786337CS
267.8849.311639549415.9824.8414.4217841917.82136737CS
527.8849.311639549415.9824.8414.4217841917.82136737CS
1567.8849.311639549415.9824.8414.4217841917.82136737CS
2607.8849.311639549415.9824.8414.4217841917.82136737CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0

Discussion

View Full Feed
janice shell janice shell 2 minutes ago
Damn, that post seems to be gone.

As to the VIP board, I don't think Amit is getting the kind of response he wanted, for the most part.
getmoreshares getmoreshares 3 minutes ago
55m bid at 4- 54m ask at 5
NBRI
iclight iclight 3 minutes ago
Stupp is more well respected AND the company paid him and he still can’t say anything good about the crappy trial’s data.
NWBO
Chartmaster Chartmaster 3 minutes ago
Thank you!
HIRU
Lime Time Lime Time 3 minutes ago
Added this, monthly dividend. Divi goes into OTC pennies. Winnings go back into a divi stock like this. It's a winning cycle and winning accounts continue to grow 🚀
GUT
Bull_Dolphin Bull_Dolphin 3 minutes ago
You'd think no one was scummier or lower than Mayorkas, but if you scrape him up you'd find Wray underneath him.
RobotDroid RobotDroid 3 minutes ago
And the replying longs feed those beast every single day. I have them both on ignore and do not suffer fools, but many here do. How ignorant is that?
NWBO
PINKPASTE PINKPASTE 3 minutes ago
Somebody got 50M on the .0003, not me.$DRNK
DRNK
The Danish Dude The Danish Dude 3 minutes ago
Coming to a prison near you. 👍🏻

https://x.com/flemmingbruce/status/1816925345741943283?s=46&t=Qud66K2UyvOImiHkUTxcjA
NWBO
Saving Grace Saving Grace 3 minutes ago
Hardly, just spoke too soon is all.

https://investorshub.advfn.com/uimage/uploads/2024/2/20/igejjgiphy.webp
BTCUSD
getmoreshares getmoreshares 3 minutes ago
the usual fri dip-- it was just 1m shares- the rest were slaps at 5
NBRI
ddls ddls 3 minutes ago
Sales-Track showing steep sales declines 2024 for (BIEL BioElectronics)
BIEL
CatfishHunter CatfishHunter 4 minutes ago
Again and for the last time. Submission was on the 28th June. Vivos is in WA. FDA HQ is in Maryland. Unless Vivos submitted after hours ECT, reception by FDA is on the 28th. And that depends on disclaimer by FDA about reception of electronically submitted docs after normal business hours.
RDGL
Chartmaster Chartmaster 4 minutes ago
Wow! Best day ever for MMM!!! Too bad I sold way too early! Still a 3 bagger though!
MMM
Legster1969 Legster1969 4 minutes ago
If you look at the ratio of buys to sells, you'll clearly notice that there is much more buying than selling. That's why I know it's just a matter of time.
NSAV
rmoss rmoss 4 minutes ago
Goop
That may be ss cause we match that penny for penny
UBQU
gemstone57 gemstone57 4 minutes ago
Thanks for the update,added more today$
MVNT
sakssey23 sakssey23 4 minutes ago
It actually disappeared. We can close green today not much remaining. Need huge slaps
HIRU
Lime Time Lime Time 4 minutes ago
Yep, Jake threw a bunch of money in this just to lose. lol

I look forward to see how the catalysts come here. Buy low and sell high is how you play this OTC
BCAP
Tha Batmannn Tha Batmannn 5 minutes ago
Knock yourself out.

Nobody reading that garbage.
MEDH
CrimsonNightRider CrimsonNightRider 5 minutes ago
Seems like a lot of drama talk for a stock that has traded less than $100 this week.


https://investorshub.advfn.com/uimage/uploads/2023/11/5/lxnflIMG_5873.gif
ASTA
newmedman newmedman 5 minutes ago
I am getting tired of our current rejection of expertise.

I'm watching you on the VIP board and I still can't fathom how you do it. LOL If that was me, my head would be spinning in circles with steam blowing out of my ears so violently that it would mute a train horn....
HoneyBager HoneyBager 5 minutes ago
Also remember the company may have a 4 day period before they must announce. At least that information is just what I’ve been hearing not exactly sure where that info get validated
RDGL

Your Recent History

NASDAQ
LENZ
LENZ Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved